|
Ensure that your vaccine orders are approved quickly by staying in compliance with Childhood Vaccine Program requirements. This training will go over everything that needs to be submitted prior to getting your orders (and transfers!) approved. We'll also share some helpful tips and have time for Q&A.
Date: July 17, 2025
Time: 12 noon
Primary Audience: Providers and Vaccine Coordinators for the Childhood Vaccine Programs
Register for July 17, 2025 webinar
In an effort to reduce vaccine loss, we are asking providers who have an excess supply of RSV and COVID-19 vaccine to advertise those excess doses for transfer on the Vaccine Advertisements page of the IIS. Providers who are in need of RSV and/or COVID-19 vaccine should first check Vaccine Advertisements for available vaccine transfers in the community before placing an order.
The Vaccine Advertisement function allows you to post vaccines that your clinic may not be able to use for transfer to other Childhood Vaccine Program providers. You can also find doses your clinic may be able to use. This is a simple and easy way to advertise or locate available vaccines when your facility is in need or has a surplus of vaccine.
For more details, please see our guide on How to Search for and Advertise Vaccines for Transfer.
Please note, you will still need approval prior to transferring vaccine. Review the vaccine transfer checklist and FAQs for additional information and guidelines for transferring vaccines.
We are pleased to invite you to participate in a two-part CDC RSV Learning Collaborative: Preventing RSV Infection in AI/AN Children Through Partnerships and Early Planning.
This learning series is designed to support IHS Areas, Tribal and Urban Indian health programs, and state/local immunization awardees in strengthening RSV immunization strategies ahead of the 2025–2026 season. Sessions will focus on early coordination, vaccine ordering, and sharing implementation best practices to protect American Indian and Alaska Native (AI/AN) infants and young children from severe RSV illness.
Session Details:
Free foldable, pocket-sized laminated schedules are still available to order. Order free immunization materials online or by email. Ordering materials online is the easiest and fastest way to place your order.
Order materials online
Order materials by e-mail
- Send an e-mail to ImmuneMaterials@doh.wa.gov. Be sure to include:
- The material(s) you want to order.
- The quantity of each material.
- Your name, address, and phone number.
For help to determine the number of MMR doses a child or adult needs, check out these helpful resources:
CDC updated its Travelers' Health: Global Measles web page to encourage all international travelers to be fully vaccinated before travel. CDC also offers resources for communities experiencing a measles outbreak including infographics for families, images to help clinic personnel identify cases, guidance for caring for patients with measles, and a Be Ready for Measles communication toolkit. Spanish-language resources are now available on the toolkit page.
The American Academy of Pediatrics released four free Red Book Online Webinars focused on measles, including:
- Spotting a Threat: Measles in Immunocompromised Children (24:40)
- Infection Prevention & Control for Measles (14:56)
- The Use of Vitamin A in the Management of Measles (5:35)
- Identifying and Diagnosing Measles in the Pediatric Setting (two parts: 5:21, 9:44)
View the webinars
On June 9, FDA (Food and Drug Administration) approved a second long-acting RSV preventive antibody, clesrovimab-cfor (Enflonsia, Merck). It is indicated for the prevention of RSV lower respiratory tract disease in neonates and infants up to age 12 months who are born during or entering their first RSV season.
On June 12, FDA expanded the age range to be 18-59 years for mResvia (RSV vaccine, Moderna). Previously, mResvia was indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV solely in those age 60 years and older.
The ACIP (Advisory Committee on Immunization Practices) votes that occurred during their meeting on April 15–16, 2025 are now adopted by the Health and Human Services Secretary, pending confirmation of a new CDC Director.
ACIP members voted to recommend in April:
| Chikungunya vaccine |
Chikungunya vaccine, virus-like particle
- ≥12 years old and traveling to a country or territory where there is a chikungunya outbreak
- May be considered for persons aged ≥12 years traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time (e.g., 6 months or more)
- lab workers with potential for exposure to chikungunya virus
Chikungunya vaccine, live attenuated
- ≥ 18 years old and traveling to a country or territory where there is a chikungunya outbreak
- May be considered for persons aged ≥ 18 years traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time (e.g., 6 months or more)
|
| Meningitis vaccine, PENMENVY (GSK) |
- May be used when both MenACWY and MenB are indicated at the same visit
- Healthy persons aged 16-23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine
- ≥10 years old and at increased risk for meningococcal disease (e.g., persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)
|
| RSV vaccine |
- 50-59 years of age at increased risk of severe RSV disease should receive a single dose of RSV vaccine (Arexy, GSK; Abrysvo, Pfizer; mResvia, Moderna). Note: RSV vaccination is currently recommended as a single dose only.
|
ACIP also met on June 25–26 and voted to recommend:
- One dose of clesrovimab, a new monoclonal antibody approved by FDA for infants whose mothers are not protected by maternal respiratory syncytial virus (RSV) vaccination. Clesrovimab is one of two RSV monoclonal antibody products available (nirsevimab is the other monoclonal antibody product).
- Reaffirmation of the recommendation for routine annual influenza vaccination for all persons aged over six months who do not have contraindications.
- Seasonal influenza vaccines for children 18 years and younger only in single-dose formulations free of thimerosal as a preservative.
- Seasonal influenza vaccines for pregnant women only in single-dose formulations free of thimerosal as a preservative.
- Seasonal influenza vaccines for all adults only in single-dose formulations that are free of thimerosal as a preservative.
The Department of Health will provide more details as soon as they are available. Please send an email to wachildhoodvaccines@doh.wa.gov or immunenurses@doh.wa.gov for any questions.
Updates to the WAIIS (WA Immunization Information System) forecasting tool took place on February 26, 2025. WA DOH has corrected doses of ‘Polio, unspecified’ in the WAIIS. The following modifications were made:
- All recorded doses of ‘Polio, unspecified’ with an administered date of 4/1/16 or later have been changed to ‘OPV bivalent ’.
This ensures that the doses are correctly evaluated by the WAIIS forecaster and could result in new patients being forecasted as needing additional polio vaccine. Please vaccinate these patients with additional doses of IPV if needed to complete the series according to CDC’s Immunization Schedule. We suggest running a Coverage Rate Report to see if new patients are forecasted for IPV.
For more information on how to enter doses when IPV or OPV is not specified, refer to Polio Vaccine Documentation in the WAIIS. Questions about this change can be directed to ImmuneNurses@doh.wa.gov.
Summer is heating up - make sure your vaccines aren't! High summer temperatures can cause vaccine storage units to run too warm or even fail. Now is a good time to review your emergency plans and have vaccine transport supplies ready in case vaccines need to be move to an emergency back-up location.
Resources:
|
